Priorix

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

22 competitors in Chickenpox

#DrugCompanyPhaseTrials

1

Zovirax

BBp Consulting, Inc

Approved

—2

Hepatitis a Vaccine

Sanofi

Phase 3

53

Zostavax

Merck & Co.

Phase 3

14

Investigational Cancer Drug

GSK

Phase 3

55

Varilrix

GSK

Phase 3

16

MMR-Vaccine

GSK

Phase 3

37

Comparator TIV

Novartis

Phase 3

18

Candidate Varicella Vaccine

GSK

Phase 3

19

Marketed Paracetamol

GSK

Phase 3

510

PCV 20

GSK

Phase 3

4Show 9 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity7 trials

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT01702428·5,016 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT02184572·1,742 enrolled

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

Completed·GSK·Phase 3·NCT02058563·996 enrolled

Show 4 more trials

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine

Completed·TThemis Bioscience GmbH·Phase 2·NCT02861586·263 enrolled

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Completed·GSK·Phase 3·NCT01627561·148 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Completed·GSK·Phase 3·NCT01621802·4,011 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Completed·GSK·Phase 3·NCT01681992·4,538 enrolled

Vaccination1 trial

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06824181·580 enrolled

Vaccine1 trial

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting·Sanofi·Phase 3·NCT06824194·2,320 enrolled

ALS1 trial

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Completed·GSK·Phase 3·NCT00326118·433 enrolled

Chickenpox1 trial

Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox

Completed·GSK·Phase 3·NCT00226499·5,803 enrolled

1 more indication

Varicella1 trial

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Completed·GSK·Phase 3·NCT00969436·450 enrolled

Details

Drug Info

Related News